In the deal, Entellus paid $25 million in cash and issued approximately 3.4 million shares of Entellus common stock, which close at $16.51 the day before the deal was announced on July 7, putting the stock portion of the deal at approximately $56.1 million.
Upon closure, Redwood City, Calif.-based Spirox will now function as an indirect, wholly-owned subsidiary of Entellus medical, the company said in an SEC filing.
As part of the deal, Entellus said it will pay an additional contingent merger consideration to Spirox’s former equity holders based on Entellus’ net revenue from sales of Spirox’s Latera device and subsequent versions.
Spirox won 510(k) clearance from the FDA for the Latera implant in July 2016.
Entellus medical shares have risen since last week, but are down 0.7% today at $17.57 as of 9:37 a.m. EDT.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.